Lanthio Pharma discovers and develops Lanthiopeptides, a new class of peptides with high target selectivity and improved “drug-like” properties. Lanthio pharma was acquired by Morphosys in 2015.
Employees: 11-50
Total raised: $6.21M
Founded date: 2010
Investors 1
| Date | Name | Website |
| 03.08.2021 | BioGenerat... | biogenerat... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.11.2012 | Series A | $6.21M | - |
Mentions in press and media 1
| Date | Title | Description |
| 28.11.2012 | Lanthio Pharma Raises €4.8M in First Close of Series A funding | Lanthio Pharma B.V., a Groningen, The Netherlands-based biopharmaceutical company focused on discovering and developing a new class of therapeutic peptides with high target selectivity and improved “drug-like” properties, has raised €4.8m i... |